Peter Kiessling, Dr. is an experienced clinical research professional with a significant background in directing clinical programs across various global organizations. Currently serving as Senior Clinical Program Director at UCB since September 2012, Peter leads the clinical development of a pioneering monoclonal antibody program targeting FcRn and supervises a cross-functional global subteam. Prior to this, Peter held the position of Division Head of Research and Development at Antisense-Pharma GmbH, where responsibilities included overseeing clinical development for an antisense candidate in oncology and collaborating with medical experts. Previous roles at CSL Behring, Omnicare, and the Max Planck Institute emphasize a long-standing involvement in clinical research and project management, with early academic contributions in muscle protein research leading to a Ph.D. in Biology from The Philipp University of Marburg.
This person is not in any teams
This person is not in any offices